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Abstract
Background: Legg-Calve-Perthes Disease (LCPD) is an idiopathic osteonecrosis of the developing femoral head
complicated by pain and disability of the hip joint. To date, the pathological mechanisms of LCPD are not well-known.
This study screened the changes in serum protein expression in patients with LCPD.
Methods: Age- and sex-matched serum samples from 10 control subjects and 10 patients with LCPD were compared
using the isobaric tags for relative and absolute quantification (iTRAQ) technique. Gene ontology analyses, KEGG pathway
and functional network analyses were performed. Proteins of interest with large differences in expression, S100-A8,
alpha-1-acid glycoprotein 1, haptoglobin and apolipoprotein E, were compared by western blotting.
Results: The disease/control ratios showed 26 proteins were significantly differentially expressed (all p < 0.05). Including
higher abundances of complement factor H (1.44), complement C4-B (1.45), isocitrate dehydrogenase [NAD] subunit
alpha (2.7) alpha-1-acid glycoprotein 1 (1.87), heptoglobin (1.53) and Ig lambda-2 chain C regions (1.46), and lower
levels of apolipoprotein E (0.50), apolipoprotein F (0.60), apolipoprotein C-III (0.69), S100-A8 (0.73), S100-A9 (0.75)
and prothrombin (0.77) in LCPD than in controls. The alpha-1-acid glycoprotein 1 and haptoglobin increases, and
apolipoprotein E and S100-A8 decreases were confirmed by western blot. KEGG pathway analysis revealed these
proteins were related to the complement and coagulation cascades, Staphylococcus aureus infection, PPAR
signaling, fat digestion and absorption, and vitamin digestion and absorption. Functional network analysis
suggested that the proteins were involved in lipid regulation.
Conclusions: The complement and coagulation cascades, and abnormal lipid metabolism may be involved in
the pathogenesis of LCPD.
Keywords: Legg-Calve-Perthes disease, Serum proteome, Isobaric tags for relative and absolute quantification,
Lipid metabolism
Background
Legg-Calve-Perthes disease (LCPD) is an idiopathic
osteonecrosis of the developing femoral head compli-
cated by pain and disability of the hip joint. The disease
affects childhood between 6 and 9 years of age. The esti-
mated annual incidence ranges from 0.2 to 19.1 per
100,000 among children under 15 years [1]. It occurs 5
times more often in boys than in girls [2]. The main
long-term problem with this disease is a permanent de-
formity of the femoral head, which increases the risk of
developing osteoarthritis in adults [3]. However, the
underlying mechanisms and determinants of LCPD are
still unclear including the proteins involved. This situation
hampers effective treatment and etiological investigation.
Coagulation abnormalities [4–6], vascular interruptions
of the blood supply to the proximal femur [7] and abnor-
mal immunological reactivity [8] are all linked to the
pathogenesis of LCPD. In addition, it has been suggested
that leptin, a lipid regulator, might play an important role
[9]. Another study showed abnormalities in the vascular
structure and function in children with LCPD disease
[10]. In experimental animal models, acute bone mor-
phogenic protein 2 (BMP2) upregulation [11], increased
vascular endothelial growth factor (VEGF) expression
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in the epiphyseal cartilage [12], and increased matrix
mineralization [13] in the immature femoral head fol-
low induction of ischemic osteonecrosis. These findings
imply that multiple pathological reactions may be in-
volved in the development of LCPD.
Comparative serum proteomic analysis has been used
for years as a potent tool for understanding the pathology
of many diseases, especially for those diseases, like LCPD,
about which we have very limited knowledge. A similar
strategy has been applied to osteonecrosis of the femoral
head in adults [14, 15]. Given that these two diseases
occur in the same location and have similar symptoms the
results of that study should also help us understand the
pathology of LCPD. Isobaric tags for relative and absolute
quantitation (iTRAQ), is a quantitative proteomic ap-
proach with relatively high throughput that allows for sim-
ultaneous identification and peptide quantification by
measuring the peak intensities of reporter ions with tan-
dem mass spectroscopy (MS/MS) that has been developed
and utilized to identify biomarkers for various disease
conditions [16, 17]. This chemical labeling method in-
volves the stable incorporation of isotopes into an amine
tagging reagent, which can then be reliably detected by
mass spectrometry, thereby permitting comparative quan-
titation of various proteins. This method has been sug-
gested to be suitable for the discovery of differentially
expressed proteins in a wide range of body fluids and
tissues, including serum and plasma [17, 18].
In this study, we performed a comparison of serum
proteomes in child patients with LCPD using the bioin-
formation match iTRAQ method, to assess the simultan-
eous expression of several serum proteins. This allowed
us to characterize the associations between differentially
expressed proteins and the incidence of LCPD.
Methods
Patients
The study included a total of 20 healthy children and 20
patients with LCPD. All the patients and the gender/age
matched healthy children were recruited between No-
vember 2011 and August 2012 from the second Hospital
affiliated to Xian Jiaotong University (Xi’an, China). The
diagnosis of LCPD was verified based upon the radio-
graphic appearance and clinical features [19]. The re-
cruited patients were diagnosed with the disease for the
first time and they had accepted no treatment including
agent, surgery or the other treatments (non-weight bear-
ing, bed rest, cast, etc.) before their blood was sampled.
Cases of multiple epiphyseal dysplasia, cerebral palsy,
and developmental hip dysplasia were excluded owing to
their known independent association with avascular ne-
crosis of the hip. The severity of the disease was evalu-
ated according to the Catterall staging system [19], there
were four stage I patients, five stage II patients and one
stage III patients. The healthy children, who had a phys-
ical examination before admission to our hospital, were
randomly enrolled to serve as the control group in the
same period by being age- and gender-matched. The re-
cruitment criteria was as follows: the healthy children
had no disease and bone disease history, with no previ-
ous or current symptoms related to the hip and a nor-
mal hip radiograph (if available) or no limitation of hip
abduction and internal rotation (in children without hip
radiographs). There were no significant differences in
body weight and height between the two groups. ITRAQ
analysis was performed for the first ten patients and ten
healthy children (clinical characteristics are showed in
Table 1). The blood sample of another 20 patients and
the age and sex matched healthy children were used to
performed west-blotting analysis (clinical characteristics
are shown in Table 2).
This study was approved by the Ethical Committee of
the Second Affiliated Hospital of Xi’an Jiaotong University,
Xi’an, China. Signed informed-consent documents
were obtained from all the study participants and
their guardians.
Protein Digestion and isobaric tags for relative and absolute
quantification (iTRAQ) labeling
Two milliliters of peripheral venous blood was obtained
from each patient in the outpatient department, and
processed to collect serum and then stored at −80 °C for
further analysis. Fourteen high-abundance proteins in
the serum pools were depleted using a multiple affinity
removal system (Agilent Human 14, Agilent Technolo-
gies, USA) following the manufacturer’s protocol. A 5
KDa ultrafiltration tube (Sartorius) was used for desalin-
ation and concentration. The protein content of the de-
pleted serum was determined by the Bradford assay
(Bio-Rad protein assay) according to the manufacturer’s
instructions.
Protein digestion was performed according to the Filter
aided sample preparation (FASP) procedure described by
Wisniewski et al. [16]. The resulting peptide mixture was
labeled using the 4-plex iTRAQ reagent (Applied Biosys-
tems). Briefly, 200 μg of peptides from each sample were
added to 30 μl of STD buffer (4 % sodium dodecyl sulfate
(SDS), 100 mM dithiothreitol (DTT), 150 mM Tris–HCl
pH 8.0). The detergent, DTT and other low-molecular-
weight components were removed using UA buffer (8 M
Table 1 Clinical characteristics in two groups for iTRAQ analysis
Group Patient group Healthy group
Sex (female /male) 1/9 1/9
Age (Years) 5.4 ± 1.9 5.5 ± 2.0
Height (cm) 111.5 ± 14.9 109.6 ± 15.1
Weight (kg) 20.5 ± 5.1 20.9 ± 4.8
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Urea, 150 mM Tris–HCl pH 8.0) by repeated ultrafiltra-
tion (Microcon units, 30 kD). Then 100 μl 0.05 M iodoa-
cetamide in UA buffer was added as a blocking agent and
the samples were incubated for 20 min in darkness. The
filters were washed with 100 μl of UA buffer three times
and then 100 μl DS buffer (50 mM triethylammoniumbi-
carbonate at pH 8.5) twice. Finally, the protein suspen-
sions were digested with 2 μg of trypsin (Promega,
Madison, USA) in 40 μl of DS buffer overnight at 37 °C,
and the resulting peptides were collected as a filtrate. The
peptide content was estimated by UV light spectral dens-
ity at 280 nm using an extinction coefficient of 1.1 of
0.1 % (g/l) solution that was calculated on the basis of the
frequency of tryptophan and tyrosine in vertebrate pro-
teins [20, 21].
For labeling, each iTRAQ reagent was dissolved in 70 μl
of ethanol and added to the respective peptide mixture.
The samples were labeled as Serum1-114, Serum2-115,
Serum3-116, and Serum4-117, and were multiplexed and
vacuum dried.
Mass Spectrum (MS) analyses
The peptide mixture was desalted on C18 Cartridges
(Empore™ SPE Cartridges C18, standard density, bed I.D.
7 mm, volume 3 ml, Sigma, St. Louis, USA), then concen-
trated by vacuum centrifugation and reconstituted in
40 μl of 0.1 % (v/v) trifluoroacetic acid. MS experiments
were performed on a Q Exactive mass spectrometer that
was coupled to Easy nLC (Proxeon Biosystems, now
Thermo Fisher Scientific). 10 μl of the sample was injected
for nanoLC-MS/MS analysis. The peptide mixture (5 μg)
was loaded onto a C18-reversed phase column (15 cm
long, 75 μm inner diameter) packed in-house with RP-
C18 5 μm resin in buffer A (0.1 % Formic acid) and sepa-
rated with a linear gradient of buffer B (80 % acetonitrile
and 0.1 % Formic acid) at a flow rate of 250 nl/min con-
trolled by IntelliFlow technology over 240 mins. MS data
was acquired using a data-dependent top10 method dy-
namically choosing the most abundant precursor ions
from the survey scan (300–1800 m/z) for HCD (higher
energy collisional dissociation) fragmentation. Determin-
ation of the target value was based on predictive auto-
matic gain control (pAGC). Dynamic exclusion duration
was 60 s. Survey scans were acquired at a resolution of
70,000 at m/z 200 and resolution for HCD spectra was set
to 17,500 at m/z 200. Normalized collision energy was
30 eV and the underfill ratio, which specifies the minimum
percentage of the target value likely to be reached at max-
imum fill time, was defined as 0.1 %. The instrument was
run with peptide recognition mode enabled.
Protein identification
MS/MS spectra were searched using MASCOT engine
(Matrix Science, London, UK; version 2.2) embedded
into Proteome Discoverer 1.3 (Thermo Electron, San
Jose, CA.) against UniProt Human database (133549 se-
quences, downloaded on March 3rd, 2013) and the
decoy database. For protein identification, the following
options were used. Peptide mass tolerance = 20 ppm,
MS/MS tolerance = 0.1 Da, Enzyme = Trypsin, Missed
cleavage = 2, Fixed modification: Carbamidomethyl (C),
iTRAQ4plex (K), iTRAQ4plex (N-term).
Gene ontology analyses
The gene ontology (GO) method is a major bioinformatics
initiative with the aim of standardizing the representation
of protein attributes across species and databases. The on-
line system provides a controlled vocabulary of terms for
describing gene product characteristics and gene product
annotation data from GO consortium members, as well as
tools to access and process this data. Each protein is char-
acterized in terms of three ontologies: molecular function,
cellular component and the involved biological process.
Using the GO database (http://www.geneontology.org/)
and Onto-Express analysis [18], the involved genes were
classified in order to gain an overall picture of potential
functions of the differentially expressed genes in this
study.
KEGG pathway analyses
The orthology of the proteins was investigated using the
Kyoto encyclopedia of genes and genomes (KEGG) data-
base, by adopting a web-based server called KAAS (KEGG
Automatic Annotation Server: http://www.genome.jp/
kegg/kaas/). The proteins were annotated with the KEGG
orthology (KO) identifiers, or the K numbers, based on
the best hit information using Smith–Waterman scores as
well as by the manual curation. Each K number represents
an ortholog group of genes, and it is directly linked to an
object in the KEGG pathway map or the BRITE functional
hierarchy. The method is based on sequence similarities,
bi-directional best hit information and some heuristics,
and has achieved a high degree of accuracy when com-
pared with the manually curated KEGG GENES database.
Functional network analyses
To investigate the direct (physical) and/or indirect (func-
tional) interactions among the identified genes, we further
utilized the search tool for the retrieval of interacting genes
Table 2 Clinical characteristics in two groups for West-blotting
verification
Group Patient group Healthy group
Sex (female /male) 3/17 3/17
Age (Years) 5.6 ± 2.1 5.8 ± 2.3
Height (cm) 113.5 ± 12.3 108.6 ± 16.3
Weight (kg) 22.5 ± 5.4 21.9 ± 5.0
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(STRING) database (http://string.embl.de/) to analyze the
functional network. The STRING database provided a
score for each gene-gene interaction, which is computed as
the joint probability of the probabilities from the different
evidence channels (protein interaction, fusion, co-expression,
text mining, etc.), correcting for the probability of randomly
observing an interaction [22]. A high database score meant
that there were high experimental or predicted evidence
for gene-gene functional interaction. Therefore a func-
tional associated network was constructed based on the
differential expression profile in the present study.
Western blotting analysis
Commercial antibodies used for western blotting valid-
ation experiments were as follows: haptoglobin (HP)
(31083) (Signalway Antibody LLC, Baltimore, USA), S100-
A8 (ab92331), and orosomucoid 1 (ORM1) (ab133642),
apolipoprotein E (APOE) (ab52607) and actin monoclonal
antibodies (all from Abcam, Cambridge, MA, USA). Proc-
essed serum from another 30 adolescents (15 LCPD pa-
tients and 15 age and sex matched healthy adolescents)
that had undergone depletion of high-abundance proteins
was used for western blotting analysis. SDS polyacryl-
amide gel electrophoresis (SDS-PAGE) was performed on
12-15 % acrylamide gels with 60 μg protein per lane, and
proteins were electrophoretically transferred onto nitro-
cellulose membranes (Millipore, Billerica, MA, USA).
Membranes were blocked with blocking buffer purchased
from LICOR (Lincoln, NE, USA) and then incubated over-
night at 4 °C with primary antibody. The dilutions were
performed as suggested by the manufacturers. The mem-
branes were washed with phosphate buffered saline (PBS)
followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA) at 37 °C for 2 hours, and
then chemiluminescence detection by ECL plus. Captured
images were analyzed using a LAS4000 (Fuji Film) and
Multi Gaugev2.0 (Fuji Film). For quantification of western
blotting data, each protein signal was quantitated and nor-
malized by the internal protein actin intensity.
Statistical analysis
The statistical significance of the differential expression
levels on proteins was tested by t-test. A protein with a
Fig. 1 Protein classification. a based on the ontology of biological processes; b based on the ontology of cellular components; c based on the
ontology of molecular functions
Liu et al. BMC Musculoskeletal Disorders  (2015) 16:281 Page 4 of 9
disease/healthy control ratio > 1.2 and p <0.05 was con-
sidered as significant. The method of false discovery rate
(FDR) was used for addressing the multiple-testing ad-




We identified 223 protein groups from a total of 2803
unique peptides. All the identified proteins were classified
using the GO annotation (http://david.abcc.ncifcrf.gov/
home.jsp) and further categorized into three functional
groups: biological processes (Fig. 1a), cellular components
(Fig. 1b) and molecular functions (Fig. 1c).
The GO analyses showed that the most common mo-
lecular function was binding activity, which included ion
binding, protein binding, carbohydrate binding, pattern
binding, cell surface binding, and lipid binding. Another
major functional category was enzyme regulation. The
most frequently encountered biological processes were
biological regulation, response to stress, localization, and
establishment of localization.
Differentially expressed proteins
There was a significant difference of expression of 26 pro-
teins that had specific functions between the disease and
control groups (shown in Table 3). Complement activation
related proteins, complement C4-B and complement fac-
tor H, were more highly expressed in the disease group.
However, the cartilage metabolism related protein S100-
A8/S100-A9 was reduced in the disease group. Further-
more, we found that the immune response related protein,
Ig kappa chain C region and Ig lambda-2 chain C region,
had significant increased expression in LCPD. And pro-
thrombin, which has a close relationship with coagulation,
was lower in the disease group.
The KEGG pathway analysis showed that the comple-
ment and coagulation cascades were the major pathways
in the study. In addition pathways related to Staphylococ-
cus aureus infection, peroxisome proliferator-activated
Table 3 Differentially Expressed Proteins in LCPD and Control Groups
Accession no. Protein description Gene name Disease/control Ratio p-value
Q8TCZ8 Apolipoprotein E APOE 0.50 <0.001
F5GXS5 Apolipoprotein F APOF 0.60 <0.001
B7Z539 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 0.67 <0.001
P02656 Apolipoprotein C-III APOC3 0.69 <0.001
P05109 S100-A8 S100A8 0.73 0.004
P01860 Ig gamma-3 chain C region IGHG3 0.74 0.006
Q59HB3 Apolipoprotein B APOB 0.74 0.007
B2R4M6 S100-A9 S100A9 0.75 0.008
P02655 Apolipoprotein C-II APOC2 0.76 0.010
P00734 Prothrombin F2 0.77 0.017
B2R701 Peptidase inhibitor 16 PI16 0.79 0.027
P11226 Mannose-binding protein C MBL2 0.79 0.030
B7Z544 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 0.80 0.040
P36980 Complement factor H-related protein 2 CFHR2 0.80 0.470
B3KWB5 Alpha-1B-glycoprotein A1BG 1.288 0.033
P01859 Ig gamma-2 chain C region IGHG2 1.315 0.020
A8K5T0 Complement factor H CFH 1.44 0.002
B7Z1F8 Complement C4-B C4B 1.45 0.001
P0CG05 Ig lambda-2 chain C regions IGLC2 1.46 0.001
A2J1M4 Rheumatoid factor RF-ET7 (Fragment) 1.46 0.001
P00738 Haptoglobin HP 1.53 <0.001
P01834 Ig kappa chain C region IGKC 1.60 <0.001
P02763 Alpha-1-acid glycoprotein 1 ORM1 1.87 <0.001
P01009 Alpha-1-antitrypsin SERPINA1 1.93 <0.001
P02647 Apolipoprotein A-I APOA1 2.0 <0.001
H0YLI6 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial IDH3A 2.7 <0.001
Liu et al. BMC Musculoskeletal Disorders  (2015) 16:281 Page 5 of 9
receptor (PPAR) signaling, fat digestion and absorption,
and vitamin digestion and absorption were also identified
(shown in Fig. 2).
To further analyze the 26 differently expressed pro-
teins using STRING, a functional associated network
was constructed (shown in Fig. 3). This indicated that
APOE was employed in the central role in the LCPD
network.
Western blotting validation
Western blot analysis of four differentially expressed pro-
teins (S100-A8, haptoglobin, alpha-1-acid glycoprotein 1
and apolipoprotein E) was used to verify our mass spec-
trometry results. They were selected for investigation based
on their interesting biological functions and high fold-
changes, as well as the availability of commercial anti-
bodies. ORM1 and HP were increased in patients with
LCPD, APOE and S100-A8 were decreased in patients with
LCPD (shown in Fig. 4). Thus, western blotting was con-
sistent with the results of the mass spectrometry analysis.
Discussion
In this study, we compared serum proteome expression
in LCPD in a Chinese Hans population, and found some
prominently differentially expressed proteins in the
LCPD patients compared with the healthy controls. The
differential serum proteomes provide new-insights into
the systemic expression of many reactions that may have
occurred in the tissues of patients with LCPD.
Abnormal coagulation has been shown to be closely re-
lated with the occurrence of LCPD [4–6]. In our study we
found that prothrombin, which is important for blood
coagulation, had a different expression level, which is con-
sistent with the previous studies [4–6].
A recent study reported that abnormalities of vascular
structure and function occur in children with LCPD [10].
We found nicotinamide adenine dinucleotide (NAD) ex-
pression was suppressed in LCPD. Activation of NAD can
prevent atherosclerosis and arterial restenosis after vascu-
lar injury by suppressing vascular smooth muscle cell pro-
liferation [23].
An immune response is involved in the pathogenesis of
many diseases, including femoral head necrosis in adult
patients [24]. A previous study showed that genetic vari-
ants of interleukin-6 were related with the occurrence of
the LCPD [8, 25]. We observed that immune response re-
lated proteins were upregulated in LCPD, revealing that an
immune response may be involved in this disease. These
proteins may also be involved in complement activation.
Fig. 2 Kegg pathway analysis. The pathways of the differentially
expressed proteins indexed by KEGG database (http://www.genome.jp/
kegg/)
Fig. 3 Differentially expressed protein interaction network analysis.
Yellow nodes represent target proteins and the green nodes
represent the related proteins. SERPINA1, serpin peptidase inhibitor,
clade A, member 1; ORM1, orosomucoid 1; HP: haptoglobin; APOA1:
apolipoprotein A1; APOB: apolipoprotein B; APOC3: apolipoprotein
C3; APOC2: apolipoprotein C2; APOE: apolipoprotein E; GSDMB:
gasdermin B; ARFGAP1: ADP-ribosylation factor GTPase-activating
protein 1; TP63: tumor protein p63; IGHG3: Ig gamma-3 chain C region;
IDH3A: isocitrate dehydrogenase 3 (NAD+) alpha; IKBKG: inhibitor of
kappa light polypeptide gene; SPP1: secreted phosphoprotein 1; FGA:
fibrinogen alpha chain; F2: prothrombin; CAV1: caveolin 1; IGKC:
immunoglobulin kappa constant; IGHA1: immunoglobulin heavy
constant alpha 1; CDK5RAP3: CDK5 regulatory subunit associated
protein 3; USF2: upstream transcription factor 2; IGHG2: immunoglobulin
heavy constant gamma 2
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The LCPD patients showed higher abundance of
complement C4-B and complement factor H, which are
involved in prohibition of complement activation. Com-
plement activation is supposed to involved in osteo-
arthritis pathogenesis [26, 27] and adult femoral head
necrosis [15]. Therefore, we supposed that cartilage de-
struction was involved in the pathogenesis of LCPD
[28–30]. Very few studies have focused on the patho-
logical role of complement factors in regulating LCPD.
Complement factors reportedly control the clearance of
necrotic or apoptotic cells in tissue remodeling. The
potent biological role of complement factor H in LCPD
is unclear. In our study, changes in the abundances of
complement factor C presumably indicated distur-
bances in the homeostasis of inflammatory, necrotic, or
apoptotic reactions in LCPD.
S100 proteins are low molecular weight (9 to 14 kDa)
intracellular calcium-binding proteins that control key cel-
lular pathways. Chondrocytes and osteoblasts have been
shown to express S100-A8 and S100-A9. Both S100-A8
and S100-A9 may contribute to calcification of the cartil-
age matrix and its replacement with trabecular bone, and
redox regulation during bone resorption [31]. They have a
possible role in cartilage repair or inflammation-induced
degradation [32]. Protein S100-A8, is supposed to be in-
volved in the pathology of osteoarthritis [33, 34], and to
have a close relationship with rheumatoid arthritis. Serum
levels of S100-A8/S100-A9 were found to correlate better
with disease activity and joint destruction in various in-
flammatory arthritis than classical markers of inflamma-
tion [35, 36]. However, both S100-A8 and S100-A9 were
decreased in the serum of LCPD patients, showing that
LCPD has a different pathogenesis to osteoarthritis.
The functional network of the differently expressed pro-
teins showed that 10 proteins, including serpin peptidase
inhibitor, clade A, ORM1, HP, transferrin, APOA1, APOB,
APOC3, APOC3, APOE, and APOF, were closely con-
nected by relatively thick lines. Based on the KEGG ana-
lysis, these proteins are functionally related to lipid
metabolism. Apolipoprotein genes have been repeatedly
associated with osteonecrosis [37, 38]. The availability of
multiple lines of evidence further strengthens the validity
of the relationship between lipid metabolism and LCPD.
Actually, abnormal lipid metabolism has been con-
sidered to be an indicator of clinical risk for osteo-
necrosis and LCPD [39, 40]. It has been shown that
lipid metabolism disorders are related to the occur-
rence of the disease [41]. Furthermore, a recent study
reported that leptin played an important role in LCPD
pathogenesis [9]. Genetic polymorphisms involved in
lipid metabolism were also associated with osteonecro-
sis of the femoral head in Chinese patients [42]. Taken
together, these results suggest that abnormal lipid me-
tabolism may play an important role in the pathology
of LCPD.
This study has some limitations. We performed the
proteomic analysis on two quite small study populations,
although we did verify four differentially expressed genes
in a larger population. Further analysis of these results
in larger study populations from different ethnic groups
would provide more weight to the results. We also did
not perform any investigation into the mechanisms sug-
gested by this study. The findings of the present study are
the first step in elucidating the proteomic regulation of
LCPD. Further Studies will functionally characterize the
biological role of the candidate proteins in modulating the
Fig. 4 Western blot analysis of four differentially expressed proteins. Relative intensities of the positively identified proteins are shown by the
histograms. Patients with Legg-Calve-Pathes disease (LCPD) displayed higher levels of a orosomucoid 1 (ORM1) and b haptoglobin (HP), and lower
levels of c apolioprotein E (APOE) and d S100-A8 than healthy controls (HC). The relative density was calculated by dividing the density of matched
spot by the density of all the matched spots in the respective gel. *indicates significant difference from the healthy volunteer group, p < 0.05
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development of LCPD. Those details will have to be re-
vealed in later studies.
Conclusion
Our serum proteomic observations suggest that multiple
pathological reactions may occur in the development of
LCPD. We have characterized the expression profile and,
by extrapolation, defined the functional relationship of a
specific set of proteins that were differentially expressed
between the LCPD and control groups. The bioinformat-
ics analyses especially highlighted the importance of ab-
normal lipid metabolism to the occurrence of LCPD.
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